intravitreal anti-vascular endothelial development element usage in France throughout COVID-19 pandemic


What The Research study Did: This research study measured modifications in making use of intravitreal (IVT) anti-vascular endothelial development aspects (anti-VEGF), the primary treatment for retinal vascular problems, given that the COVID-19 pandemic began in France.

Authors: Sophie Billioti de Gage, Pharm.D., P.D., of EPI-PHARE, French National Company for Medicines and Health Products Security, French National Medical Insurance in Saint-Denis, France, is the matching author.

To access the embargoed research study: Check Out our For The Media site at this link https://media.jamanetwork.com/

( doi:10.1001/ jamaophthalmol.2020.5594)

Editor’s Note: Please see the short article for extra info, consisting of other authors, author contributions and associations, dispute of interest and monetary disclosures, and financing and assistance.

###

Media advisory: The complete research study is connected to this press release.

Embed this link to supply your readers open door to the full-text short article This link will be live at the embargo time https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2020.5594?guestAccessKey=4c61f110-140e-479d-a7a6-6f2f22c034ad&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=121720 .

Disclaimer: AAAS and EurekAlert! are not accountable for the precision of press release published to EurekAlert! by contributing organizations or for making use of any info through the EurekAlert system.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *